Drug intelligence / Profile preview

recombinant human alpha-1 antitrypsin

Development stage: Preclinical
Lead developer: Kamada
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous, Inhalation

Overview

Recombinant human Alpha-1 Antitrypsin (rhAAT) is a bioengineered glycoprotein serine protease inhibitor being developed through a collaboration between Kamada and Yissum, the technology transfer company of the Hebrew University of Jerusalem. This recombinant protein is designed to inhibit neutrophil elastase, thereby preventing excessive tissue proteolysis in patients with Alpha-1 Antitrypsin Deficiency (AATD). The project utilizes a robust eukaryotic expression system to maximize protein yield and functionality, aiming to provide a recombinant alternative to plasma-derived AAT products like Glassia to address supply limitations and explore additional therapeutic indications beyond AATD.

Brand names: Dermolastin
Other names: rhAATrecombinant human Alpha-1 Antitrypsin

Targets

F2 (Thrombin)ELANE (Human Neutrophil Elastase)CTRC (Chymotrypsin C)PA (Influenza polymerase acidic protein)PRSS1 (Trypsin family)PLG (Plasminogen)

Beyond the preview

Go deeper on recombinant human alpha-1 antitrypsin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human alpha-1 antitrypsin.

Explore the full profile